



1 **Supplementary Information**

2 **Figure S1. BLT1-expressing DCs exist in both macrophage and monocyte depleted**
 3 **CD11c+/MHC class II+ DC populations.**

4 A. Splenic BLT1^{hi} and BLT1^{lo} DCs were evaluated in F4/80+ macrophage-depleted
 5 CD11c+/MHC class II+ DC populations. B. Splenic BLT1^{hi} and BLT1^{lo} DCs were
 6 evaluated in Ly-6C+ monocyte-depleted CD11c+/MHC class II+ DC populations. Red
 7 square: BLT1^{hi} DCs; Black square: BLT1^{lo} DCs.

8

9




10

11 **Figure S2. Comparative analysis of cell surface antigens between BLT1^{hi} and BLT1^{lo}**
12 **DCs.**

13 Splenic BLT1^{hi} and BLT1^{lo} DCs were stained with antibodies specific for MHC class II,
14 CD80, and CD86. Red line: BLT1^{hi} DCs; Blue line: BLT1^{lo} DCs.

15

16



17

18

19 **Figure S3. BLT1^{hi} DCs but not in BLT1^{lo} DCs express BLT1 at mRNA, protein and**

20 **functional levels. (A)** Total RNA was extracted from sorted BMDC-derived BLT1^{hi} and

21 BLT1^{lo} DCs and subjected to QPCR analysis. GAPDH was used as an internal control

22 (n=4; Error bars indicate the S.E.M.). *, $P < 0.05$; unpaired Student's *t*-test. **(B)**

23 The microsomal fraction was extracted from BM-derived BLT1^{hi} and BLT1^{lo} DCs, and

24 subjected to western blot analysis. Na⁺-K⁺ ATPase was used as a loading control. KO,

25 microsomal fraction from BMDCs derived from BLT1 systemic knockout mice. P,

26 positive control (microsomal fraction from CHO cells stably-expressing mouse BLT1).

27 N, negative control (microsomal fraction from CHO cells). **(C)** Sorted BLT1^{hi} and BLT1^{lo}

28 DCs were treated with 1 and 100 nM LTB₄. Thirty minutes after the stimulation, proteins

29 were extracted and subjected to western blotting to detect phosphorylated ERK1/2 and

30 pan-ERK2. Actin was used as a loading control.

31

32



33


34 **Figure S4. Generation of LTA₄H knockout mouse by CRISPR/Cas9 system.**

35 Recognition site of AatII was abrogated by CRISPR/Cas9. Genomic DNA from mouse

36 tail was used for PCR and AatII enzyme cut. Deletion of AatII site was confirmed in KO

37 strains.

38



39

40

41 **Figure S5. Generation of DC-specific BLT1 conditional knockout mice. (A)** Genomic42 DNA from BMDCs was used for genotyping. Primer position was indicated Fig. 2H. **(B)**

43 Cell-specific BLT1 knockout was confirmed by QPCR analysis of total RNA extracted

44 from BMDCs. GAPDH was used as an internal control. **, $P < 0.01$. **(C)** Genomic DNA


45 from splenic DCs was used for genotyping. Primer position was indicated Fig. 2H.

46

47

48

49



50

51 **Figure S6. Migration of BLT1^{hi} and BLT1^{lo} DCs *in vivo* in another experiment.**52 Sorted BLT1^{hi} and BLT1^{lo} DCs were stained with CMFDA and CMTPIX, respectively.53 Stained DCs were mixed at a 1:1 ratio (total cell numbers: 2×10^6 cells) and injected into

54 the footpad. Popliteal lymph nodes were assessed by two-photon microscopy 24 hours

55 after DC transfer. Representative photos are shown. Bars indicate 100 μm.

56

57

58

59

60

61

62

63

64


65

66

67

68


69



70

71 **Figure S7. Comparative transcriptome analysis of BLT1^{hi} and BLT1^{lo} DCs.** Cluster
 72 dendrogram showing transcriptome profiling of 209 types of hematopoietic and non-
 73 hematopoietic cells, including BLT1^{hi} and BLT1^{lo} DCs. Gene sets (772 probes) showing
 74 differences in signal values (-fold change > 128) among cells, were used for cluster
 75 analysis. Red line indicates BLT1^{hi} DCs (BLT1hi 1: BLT1^{hi} DCs after sorting; BLT1hi
 76 2: BLT1^{hi} DCs incubated in DC medium for 4 hours) and BLT1^{lo} DCs (BLT1lo 1; BLT1^{lo}
 77 DCs after sorting; BLT1lo 2; BLT1^{lo} DCs incubated in DC medium for 4 hours).
 78

79




80

81

82 **Figure S8. The LTB₄-BLT1 axis does not affect distinct cytokine expression in**
 83 **BLT1^{hi} and BLT1^{lo} DCs.** (A, B, C) BLT1^{hi} and BLT1^{lo} DCs were pretreated for 30 min
 84 with the BLT1 antagonist U75302 (1 μM) followed by CpG DNA (500 nM) for 4 hours.
 85 Expression of IL-12p35 (A), IL-12p40 (B), and IL-2 mRNA (C) was measured by QPCR
 86 (n=3; Error bars indicate the S.E.M.).

87


88



89

90 **Figure S9. Several histone modifications (H3K9K14ac, H3K27ac, H3K4me1,**
 91 **H3K4me3, H3K27me3, and H3K9me3) and transcription factor bindings (Cebpb**
 92 **and Irf1) to the IL-12p35 (A), and IL-2 (B) loci in mouse dendritic cells.** Data were
 93 obtained by ChIP-Atlas and visualized with IGV viewer. Arrows indicate the direction of
 94 transcription. H3 acetylation is a mark for actively transcribed region. H3K4me1 is a
 95 mark of enhancer region. H3K4me3 is a promoter mark. Interferon regulatory factor
 96 (IRF) 1 localizes in promoter and enhancer/promoter boundary of IL-12a locus, whereas
 97 Cebpb localizes in enhancer region of IL-2 locus.

98



100 **Figure S10. Expression of CCR7 mRNA and protein by BLT1^{hi} and BLT1^{lo} DCs.**

101 (A) Total RNA was extracted from both DC subsets and assessed by QPCR analysis.

102 GAPDH was used as an internal control. (B, C) BMDCs (B) or splenic DCs (C) were

103 stained with CD11c, MHC class II, BLT1 and CCR7 antibodies.

104

105